UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

Blood, 2012-01, Vol.119 (2), p.488-493

2012

Volltextzugriff (PDF)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia

Haematologica (Roma), 2019-07, Vol.104 (7), p.1451-1459

2019

Volltextzugriff (PDF)

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

Blood, 2017-03, Vol.129 (10), p.1333-1342

2017

Volltextzugriff (PDF)

Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia

Haematologica (Roma), 2017-09, Vol.102 (9), p.1567-1577

2017

Volltextzugriff (PDF)

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

Haematologica (Roma), 2017-08, Vol.102 (8), p.1424-1431

2017

Volltextzugriff (PDF)

Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3898-3905

2013

Volltextzugriff (PDF)

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis

Haematologica (Roma), 2017-07, Vol.102 (7), p.1281-1290

2017

Volltextzugriff (PDF)

DNA Damage-Induced Accumulation of Centrosomal Chk1 Contributes to its Checkpoint Function

Cell cycle (Georgetown, Tex.), 2007-10, Vol.6 (20), p.2541-2548

2007

Volltextzugriff (PDF)

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis

Haematologica (Roma), 2008-03, Vol.93 (3), p.459-462

2008

Volltextzugriff (PDF)

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens

Journal of clinical oncology, 2015-04, Vol.33 (12), p.1371-1378

2015

Volltextzugriff (PDF)

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Blood, 2017-08, Vol.130 (5), p.632-642

2017

Volltextzugriff (PDF)

Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary

Clinical chemistry (Baltimore, Md.), 2024-01, Vol.70 (1), p.297-306

2024

Volltextzugriff (PDF)

Treatment of AL amyloidosis with bendamustine: a study of 122 patients

Blood, 2018-11, Vol.132 (18), p.1988-1991

2018

Volltextzugriff (PDF)

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Blood, 2016-07, Vol.128 (4), p.594-602

2016

Volltextzugriff (PDF)

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

The Lancet (British edition), 2024-08, Vol.404 (10452), p.527-539

2024

Volltextzugriff (PDF)

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Blood, 2014-05, Vol.123 (19), p.2960-2967

2014

Volltextzugriff (PDF)

AL Amyloidosis — Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells

Blood, 2018-11, Vol.132 (Supplement 1), p.187-187

2018

Volltextzugriff (PDF)

Reply to R. Warsame et al

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3976-3977

2015

Volltextzugriff (PDF)

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

Blood, 2010-07, Vol.116 (4), p.522-528

2010

Volltextzugriff (PDF)

RAS activation and CDKN2A deletion to predict prognosis in cancer of unknown primary

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13026-e13026

2019

Volltextzugriff (PDF)

PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.1472-1472

2018

Volltextzugriff (PDF)

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Blood, 2020-11, Vol.136 (Supplement 1), p.10-11

2020

Volltextzugriff (PDF)

Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis

Blood, 2015-12, Vol.126 (23), p.1790-1790

2015

Volltextzugriff (PDF)

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)

Blood, 2011-04, Vol.117 (14), p.3809-3815

2011

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAmyloid

KollektionPublisher or Other Site

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(19)
Female
(16)
Male
(16)
Hematology
(15)
Middle Aged
(14)
Adult
(13)
Aged
(12)
Amyloidosis - Genetics
(7)
Prognosis
(7)
Biological And Medical Sciences
(6)
Chromosome Aberrations
(6)
Disease-Free Survival
(6)
Hematologic And Hematopoietic Diseases
(6)
Medical Sciences
(6)
Aged, 80 And Over
(5)
Adolescent
(4)
Amyloidosis - Diagnosis
(4)
Amyloidosis - Mortality
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(33)
Haematologica
(5)
Journal Of Clinical Oncology
(4)
Biology Of Blood And Marrow Transplantation
(1)
Cell Cycle
(1)
Cell Cycle/cell Cycle
(1)
Clinical Chemistry
(1)
The Lancet
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis

DNA Damage-Induced Accumulation of Centrosomal Chk1 Contributes to its Checkpoint Function

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary

Treatment of AL amyloidosis with bendamustine: a study of 122 patients

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

AL Amyloidosis — Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells

Reply to R. Warsame et al

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

RAS activation and CDKN2A deletion to predict prognosis in cancer of unknown primary

PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)

Aktive Filter

Suchergebnisse filtern